Patent · US Active

Sequestered antagonist formulations

US8465774B2 · kind B2 · utility

45Cited by

200References

137Claims

0Family size

Assignee

PURDUE PHARMA L.P. · US

Inventors

Christopher Breder · Bethesda, US
Benjamin Oshlack · Boca Raton, US
Curtis Wright · Gloucester, US

Key dates

Filing date	Feb 13, 2006
Grant date	Jun 18, 2013
Priority date	—
Expiry date	Jun 1, 2026

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P29/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact, such that the ratio of the mean Cmax of the antagonist after single dose oral administration of the dosage form after tampering to the mean Cmax of antagonist after single dose oral administration of an intact dosage form is at least 1.5:1.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.